Agora Open Science Trust’s wholly owned open science drug development company, M4K Pharma, has nominated M4K-2009 as the lead development candidate for diffuse intrinsic pontine glioma (DIPG). The ALK2 inhibitor program is now advancing into IND-enabling studies for this pediatric brain cancer.
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by E3 ubiquitin ligases.
Synnovation Therapeutics Inc. has described heterocyclic compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors reported to be useful for the treatment of cancer.
Lanova Medicines Ltd. has synthesized antibody-drug conjugates (ADCs) comprising antibodies targeting sialyl-Tn antigen (STn) linked to an exatecan derivative through a linker reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of solid cancers and hematological cancers.
The overexpression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is tied to poor prognosis in several cancer types, including osteosarcoma and Ewing sarcoma, and is therefore a potential therapeutic target in these cancers. In this regard, Avammune Therapeutics Inc. is developing an ENPP1 inhibitor – AVA-NP-695.
Receptor-interacting protein kinase 1 (RIPK1) helps promote the survival of cancer cells, and degrading it can sensitize tumors to immunotherapy against PD-1. Degrading the entire protein seems to be essential: merely blocking its kinase activity does not sensitize tumors.
Avencell Therapeutics Inc. has received clinical trial clearances from the FDA and EMA to conduct a phase I/II trial (Quadvance) of AVC-203 for the treatment of relapsed or refractory B-cell malignancies.
RSS
